Deep multimodal fusion of patho-radiomic and clinical data for enhanced survival prediction for colorectal cancer patients.
1/5 보강
This study introduces PRISM-CRC, a novel deep learning framework designed to improve the diagnosis and prognosis of colorectal cancer (CRC) by integrating histopathology, radiology, endoscopy and clin
APA
Shi R, Sun J, et al. (2025). Deep multimodal fusion of patho-radiomic and clinical data for enhanced survival prediction for colorectal cancer patients.. NPJ digital medicine, 9(1), 86. https://doi.org/10.1038/s41746-025-02210-z
MLA
Shi R, et al.. "Deep multimodal fusion of patho-radiomic and clinical data for enhanced survival prediction for colorectal cancer patients.." NPJ digital medicine, vol. 9, no. 1, 2025, pp. 86.
PMID
41350716
Abstract
This study introduces PRISM-CRC, a novel deep learning framework designed to improve the diagnosis and prognosis of colorectal cancer (CRC) by integrating histopathology, radiology, endoscopy and clinical data. The model demonstrated high accuracy, achieving a concordance index of 0.82 for predicting 5-year disease-free survival and an AUC of 0.91 for identifying microsatellite instability (MSI) status. A key finding is the synergistic power of this multimodal approach, which significantly outperformed models using only a single data type. The PRISM-CRC risk score proved to be a strong, independent predictor of survival, offering more granular risk stratification than the traditional TNM staging system. This capability has direct clinical implications for personalizing treatment, such as identifying high-risk Stage II patients who might benefit from adjuvant chemotherapy. The study acknowledges limitations, including a modest performance decrease due to "domain shift" and classification errors in morphologically ambiguous cases, highlighting the need for future prospective trials to validate its clinical utility.
같은 제1저자의 인용 많은 논문 (5)
- Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone Therapy.
- The Germline HSD3B1 Variant Is Associated With Response to Androgen Deprivation Therapy and Abiraterone but not With Response to Enzalutamide in Chinese Prostate Cancer Patients.
- WTAP stabilized by USP7 contributes to enzalutamide resistance in prostate cancer via mediating AKT mA-modification.
- Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW.
- Cancer-associated fibroblast-derived COL17A1 promotes gemcitabine resistance and tumorigenesis in pancreatic cancer cells by interacting with ACTN4.